Abivax S.A.
- Country
- 🇫🇷France
- Ownership
- -
- Employees
- 61
- Market Cap
- $752.4M
- Introduction
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis ...
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Abivax S.A.
- Registration Number
- NCT03905109
- Locations
- 🇧🇪
University Hospitals Leuven - campus Gasthuisberg, Leuven, Belgium
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 48
- Registration Number
- NCT03897543
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 60
- Registration Number
- NCT03813199
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇨🇿Fakultni Tomayerova nemocnice, Praha, Czechia
🇨🇿Revmatologicky ustav, Praha, Czechia
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 254
- Registration Number
- NCT03760003
- Locations
- 🇺🇸
Atlanta Center for Gastroenterology, P.C, Decatur, Georgia, United States
🇺🇸UCSD Health System, San Diego, California, United States
🇺🇸Central Texas Clinical Research, LLC, Austin, Texas, United States
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 22
- Registration Number
- NCT03368118
- Locations
- 🇧🇪
Department of Gastroenterology - University hospitals Leuven, Leuven, Belgium
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 32
- Registration Number
- NCT03093259
- Locations
- 🇦🇹
Univ.-Klinik für Innere Medizin I, Innsbruck, Austria
🇨🇿Klinické centrum ISCARE, Praha, Czechia
🇫🇷CHU de Nantes, Nantes, France
A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 36
- Registration Number
- NCT02990325
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Catalogna, Spain
ABX464 First in Man Study
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT02792686
- Locations
- 🇫🇷
Centre Cap, Montpellier, France
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT02735863
- Locations
- 🇧🇪
C.H.U. Saint-Pierre, Bruxelles, Belgium
🇧🇪Ghent University Hospital, Ghent, Belgium
🇧🇪CHU Sart Tilman, Liège, Belgium
Food Effect on Pharmacokinetic Parameters of ABX464
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 48
- Registration Number
- NCT02731885
- Locations
- 🇲🇺
CAP Research, Sayed Hossen road, Phoenix, Mauritius